Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. (28th November 2013)

• Record Type: Journal Article
• Authors: Volavka, Jan; Czobor, Pál; Citrome, Leslie; Van Dorn, Richard A.
• Is Part Of: CNS spectrums. Volume 19:Number 5(2014:Oct.)
• Page Start: 374
• Page End: 381
• Publication Date: 2013-11-28
• Subjects: Neuropsychiatry -- Periodicals; Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; 616.8005
• DOI: 10.1017/S1092852913000849
• Languages: English
• ISSNs: 1092-8529

Abstract

<abstract abstract-type="normal"> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <sec id="abs1" sec-type="intro"> <title>Introduction</title> <p>Aggressive behavior can be a dangerous complication of schizophrenia. Hostility is related to aggression. This study aimed to compare the effects of olanzapine, perphenazine, risperidone, quetiapine, and ziprasidone on hostility in schizophrenia.</p> </sec> <sec id="abs2" sec-type="methods"> <title>Methods</title> <p>We used the data that were acquired in the 18-month Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. We analyzed the scores of the Positive and Negative Syndrome Scale (PANSS) hostility item in a subset of 614 patients who showed at least minimal hostility (a score ≥ 2) at baseline.</p> </sec> <sec id="abs3" sec-type="results"> <title>Results</title> <p>The primary analysis of hostility indicated an effect of difference between treatments (F<sub>4, 1487</sub> = 7.78, <italic>P</italic> < 0.0001). Olanzapine was significantly superior to perphenazine and quetiapine at months 1, 3, 6, and 9. It was also significantly superior to ziprasidone at months 1, 3, and 6, and to risperidone at months 3 and 6.</p> </sec> <sec id="abs4" sec-type="discussion"> <title>Discussion</title> <p>Our results are consistent with those of a similar post<italic>-</italic>hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride.</p> </sec> <sec id="abs5" sec-type="conclusion"> <title>Conclusion</title> <p>Olanzapine demonstrated advantages in terms of a specific antihostility effect over the other antipsychotics tested in Phase 1 of the CATIE trial.</p> </sec> </abstract>